Natco Pharma is currently frozen on the 5% upper  circuit at Rs.1114.75 the moment it opened for trading today. Yesterday too, it breached the upper circuit at Rs.1071.90.

The stock has been hitting the ceiling, reacting to the very good news for the company that it has won another battle in IP for licensing of its anti-cancer drugs. The Bombay HC yesterday upheld the compulsory licence granted to Natco for German drug major Bayer’s patented kidney cancer drug Nexavar.

This is great news not just for the company but also for patients as they will now get access to drugs at much cheaper rates. Natco’s generic version of the same drug is priced at Rs.8800 for a monthly therapy while that of Bayer’s Nexavar, for the very same drug costs Rs.2.8 lakh per month.